anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Congenital proximal renal tubular acidosis (pRTA) is a rare systemic disease caused by mutations in the SLC4A4 gene that encodes the electrogenic sodium bicarbonate cotransporter, NBCe1. The major NBCe1 protein variants are designated NBCe1-A, NBCe1-B, and NBCe1-C. NBCe1-A expression is kidney-specific, NBCe1-B is broadly expressed and is the only NBCe1 variant expressed in the heart, and NBCe1-C is a splice variant of NBCe1-B that is expressed in the brain. No cardiac manifestations have been reported from patients with pRTA, but studies in adult rats with virally induced reduction in cardiac NBCe1-B expression indicate that NBCe1-B loss leads to cardiac hypertrophy and prolonged QT intervals in rodents. NBCe1-null mice die shortly after weaning, so the consequence of congenital, global NBCe1 loss on the heart is unknown. To circumvent this issue, we characterized the cardiac function of NBCe1-B/C-null (KOb/c) mice that survive up to 2 months of age and which, due to the uninterrupted expression of NBCe1-A, do not exhibit the confounding acidemia of the globally null mice. In contrast to the viral knockdown model, cardiac hypertrophy was not present in KOb/c mice as assessed by heart-weight-to-body-weight ratios and cardiomyocyte cross-sectional area. However, echocardiographic analysis revealed reduced left ventricular ejection fraction, and intraventricular pressure-volume measurements demonstrated reduced load-independent contractility. We also observed increased QT length variation in KOb/c mice. Finally, using the calcium indicator Fura-2 AM, we observed a significant reduction in the amplitude of Ca2+ transients in paced KOb/c cardiomyocytes. These data indicate that congenital, global absence of NBCe1-B/C leads to impaired cardiac contractility and increased QT length variation in juvenile mice. It remains to be determined whether the cardiac phenotype in KOb/c mice is influenced by the absence of NBCe1-B/C from neuronal and endocrine tissues.
This project will be achieved by using a publicly available data set (Behavioral Risk Factor Surveillance System, 2017). The subjects from the data set will be selected on their pulmonary status; The control group are subjects without pulmonary diseases and they will be included as (control group).
The carcinogenicity of a 1% clindamycin phosphate gel similar to CLINDAGEL was evaluated by daily application to mice for 2 years. The daily doses used in this study were approximately 3 and 15 times higher than the human dose of clindamycin phosphate from 5 mL of CLINDAGEL, assuming complete absorption and based on a body surface area comparison. No significant increase in tumors was noted in the treated animals.

A 1% clindamycin phosphate gel similar to CLINDAGELcaused a statistically significant shortening of the median time to tumor onset in a study in hairless mice in which tumors were induced by exposure to simulated sunlight.

Genotoxicity tests performed included a rat micronucleus test and an Ames Salmonella reversion test. Both tests were negative. Reproduction studies in rats using oral doses of clindamycin hydrochloride and clindamycin palmitate hydrochloride have revealed no evidence of impaired fertility.
Patients refractory (MR, NC or PD) to VAD or VAD-like therapy. Patients should proceed directly to PAD therapy. Patients with NC or PD may proceed to PAD after a minimum of two cycles of VAD or VAD-like therapy or a minimum of 4 cycles, if MR.
Patient identification form, psychological evaluation form and mental health form were filled in for the control group. At the end of 6 weeks, the psychological evaluation form and the mental well-being form were filled again without any intervention.
PURPOSE: To investigate the impact of 3D-printed temporal bone models with two different material transparencies on trainees' mastoidectomy performance.
METHODS: Eleven ORL residents performed two anatomical mastoidectomies with posterior tympanotomy on two 3D-printed models with different transparency and VR simulation training. Participants where divided into two groups based on their experience. Within each group participants were randomized to start with the model printed in a completely opaque material or in a material featuring some degree of transparency. After drilling on 3D-printed models, the participants performed two similar mastoidectomies on human cadavers: one on the left side of one cadaver and one on the right side of another cadaver. After drilling 3D-printed models and cadavers, the final-product performances were evaluated by two experienced raters using the 26-item modified Welling Scale. Participants also evaluated the models using a questionnaire.
RESULTS: Overall, the participants performed 25 % better on the 3D-printed models featuring transparency compared to the opaque models (18.6 points vs 14.9 points, mean difference = 3.7, 95 % CI 2.0-5.3, P < 0.001)). This difference in performance was independent of which material the participants had drilled first. In addition, the residents also subjectively rated the transparent model to be closer to cadaver dissection. The experienced group starting with the 3D-printed models scored 21.5 points (95 % CI 20.0-23.1), while the group starting with VR simulation training score 18.4 points (95 % CI 16.6-20.3).
CONCLUSION: We propose that material used for 3D-printing temporal bone models should feature some degree of transparency, like natural bone, for trainees to learn and exploit key visual cues during drilling.
The present disclosure relates in part to extracts of cranberry ( Vaccinium macrocarpon ) comprising an enriched amount of certain compounds having anti-infective activity, e.g. antibacterial and/or antifungal activity, e.g. activity against  C. albicans . Another aspect of the disclosure relates to combined cranberry and cinnamon extracts. In certain embodiments, these combined extracts have been optimized to control urinary tract infections caused by  E. coli, S. aureus  and  C. albicans . Certain embodiments of the extract are enriched in bioactive compounds that have been shown to inhibit  C. albicans  adhesion and/or biofilm formation and its growth in vitro. In another aspect of the disclosure, the extracts are enriched in bioactives derived from cranberry and cinnamon that have been shown to inhibit the attachment and the growth of common urinary tract pathogens like  E. coli, S. aureus  and  C. albicans.
Propofol/remifentanil group. Patients in group P will be given propofol and remifentanil during the operation, the speeds are 50\~75 μg/kg/min and 0.2\~0.4 μg/kg/min, respectively.
Participants will receive Treatment A (mitapivat tablet, orally, under fasted conditions once on Day 1 of Period 1) followed by Treatment B (mitapivat coated granules, orally, under fasted conditions once on Day 1 of Period 2) followed by Treatment C (mitapivat coated granules, with a strawberry yogurt, orally once on Day 1 of Period 3) followed by Treatment D (mitapivat coated granules, with a chocolate pudding, orally once on Day 1 of Period 4). Each Treatment Period will be separated by a Washout Period of 7 days.
1489780 Stable prostaglandin composition YAMANOUCHI PHARMACEUTICAL CO Ltd 28 Oct 1974 [2 Nov 1973 25 June 1974] 22569/77 Heading A5B A stable composition is prepared by adding to a compound of the prostaglandin E group a pharmaceutically acceptable watersoluble salt of deoxycholic acid and subjecting the mixture to lyophilization. The prostaglandin compound may be prostaglandin E 1 , E 2  or E 3 , 16-methyl-prostaglandin E 2 , 3, 16 (R)- dimethyl-prostaglandin E 2 , 17-oxo-15-epi-prostaglandin E 2 , or 16 (R)-hydroxy-prostaglandin E 2 . The deoxycholic acid salt may be that of arginine, lysine or an alkali metal. Water may be added to form a solution which is lyophilized. As a preliminary step the prostaglandin may be dissolved in an organic solvent, which is then removed. The composition may be dissolved in water and injected.
PCT No. PCT/US92/08965 Sec. 371 Date Jun. 14, 1994 Sec. 102(e) Date Jun. 14, 1994 PCT Filed Oct. 16, 1992 PCT Pub. No. WO93/08806 PCT Pub. Date May 13, 1993The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs a blocking agent such as C5 ester derivatives, or 13-(substituted mercapto) derivatives of tetracycline, in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously, sequentially or concurrently. In another embodiment, C5 ester novel compositions are provided which may be administered alone against, for example, a sensitive or resistant strain of gram positive bacteria such as S. aureus and E. faecalis. The concomitantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state.
In Part 1, the first cohort will receive JNJ-63723283 at a starting dose of 80 milligram (mg), intravenous (IV) every 2 weeks. JNJ-63723283 doses will be escalated following a modified Continual Reassessment Method (mCRM). Multiple doses, dose administration routes (subcutaneous \[SC\] or IV), and dose schedules may be explored. In Part 2, participants will receive JNJ-63723283 at the recommended Phase 2 dose (RP2D) determined in Part 1. In Part 3, participants will receive JNJ-63723283 to evaluate pharmacokinetic (PK), pharmacodynamic (PD) and safety. In Part 4, participants will receive JNJ-63723283 at the dose level determined in Part 3. Additional cohorts may be enrolled in Part 4.
INTRODUCTION: Osteoporosis, a disease of reduced bone mass and microstructural deterioration leading to fragility fractures, is becoming more prevalent as aging progresses, significantly increasing the socioeconomic burden. In past studies, there has been a growing awareness of the harmful effects of heavy metals on bone, with cadmium being a significant exposure factor. The purpose of this study was to look into the association between adult bone mineral density(BMD) and blood cadmium levels.
METHODS: Based on information from the 2013-2014, 2017-2018 NHANES, weighted multiple regression, generalized weighted modeling, and smoothed curve fitting were utilized to investigate the association between blood cadmium and femur BMD. Furthermore, subgroup analyses were conducted to investigate any differences in the associations between age, sex, race, chronic kidney disease, and diabetes.
RESULTS: In 2,146 participants, blood cadmium levels and total femur [-0.02 (-0.03, -0.01), 0.0027], femoral neck [-0.01 (-0.02, -0.00), 0.0240], femoral trochanter [-0.01 (-0.02, -0.00), 0.0042], and intertrochanteric femoral trochanter [-0.02 (-0.03, -0.00), 0.0101] BMD were negatively correlated. Subgroup analyses showed that this association was more pronounced in women, non-Hispanic white people and other Hispanics, and those with chronic kidney disease and diabetes. Our results pointed to a negative relationship between femoral BMD and blood cadmium. This negative association varied by age, sex, race, diabetes, and chronic kidney disease. In particular, bone mineral density was more significantly negatively affected by blood cadmium levels in groups with diabetes and chronic kidney disease.
CONCLUSION: Our findings demonstrated a significant negative association between blood cadmium levels and bone mineral density in a population of U.S. adults.
The present invention discloses a dynamic plantar pressure sensing system. The dynamic plantar pressure sensing system includes a pressure sensing insole, a signal processing device and a cloud server. The pressure sensing insole is placed inside a shoe body and has a signal collector. The pressure sensing insole senses a plantar pressure signal of a user and transmits the sensed plantar pressure signal to the signal processing device through the signal collector. The signal processing device is used to receive pressure information transmitted by the signal collector and upload the pressure information to the cloud server. The cloud server analyzes the foot status of the user based on the plantar pressure signal, and then sends it back to the signal processing device for the user's reference.
Postpartum depression (PPD) occurs in approximately 10% to 16% of mothers who have recently delivered babies. The impact of PPD is profound, causing considerable emotional pain for the mother as well as possible disturbances in infant development and later child adjustment. If left untreated, the mother's depression may cause strain on family life and her relationship with her child. Further research is needed to discover treatments to effectively reduce the risk of experiencing PPD. Despite preliminary findings that suggest that psychosocial treatments may prevent postpartum mood disturbances, few studies have examined the effects of preventive therapy to reduce PPD in women at risk for PPD. An area of even greater neglect is the testing of such a treatment for financially disadvantaged women, who represent a group at high risk for PPD and a group less likely to access treatment for depression than middle-class women. The Postpartum Prevention Program (PPP), an interpersonal therapy program targeting factors that may play a significant role in the development of PPD, may be helpful in reducing the occurrence of PPD. This study will compare the effectiveness of PPP to enhanced care as usual (ECU) in preventing PPD in financially disadvantaged women who are pregnant.

Participation in this single-blind study will last until 1 year after delivery. All potential participants will answer an initial questionnaire concerning stresses that may increase the risk of depression, including relationship and emotional difficulties. Selected participants will then undergo an interview about symptoms of depression, emotional difficulties, and alcohol and drug use. Participants identified as having depression will be provided appropriate referrals for treatment and their study participation will end. Participants invited to continue with the study will be randomly assigned to receive PPP or ECU. Participants assigned to receive PPP will attend four weekly 90-minute group sessions prior to delivery and one individual 50-minute booster session within 2 weeks of delivery. During these sessions, participants will learn ways to manage stress and negative feelings and how to access social support resources. Participants assigned to ECU will receive the usual medical care provided for pregnant women, educational material on PPD, and a list of referrals and resources.

All participants will complete questionnaires and interviews about their emotional difficulties, relationships with others, and use of services for these difficulties prior to treatment assignment; 4 weeks after treatment assignment; 3 weeks after delivery; and 3, 6, and 12 months after delivery. Participants will also be seen briefly at the hospital at the time of delivery and 3, 6, and 12 months after delivery to assess mother-infant relationships. All questionnaires and assessments will take between 60 and 90 minutes to complete.
The invention discloses a cold medicine with an effect of dispelling effects of alcohol and a preparation method of the cold medicine. The cold medicine is prepared from the following raw materials in parts by weight: calculus bovis, ginger, puerarin, blueberry leaves, mint, bupleurum, phillyrin, phragmites communistrin, poria cocos, pericarpium citri reticulatae, fructus schizandrae, herba artemisiae scopariae, citrus, fructus cnidii, starch, microcrystalline cellulose, a condiment, hydrolase, ethyl alcohol and an additive. The preparation method comprises the following steps of collecting volatile oil; preparing a mixed extracting solution A; preparing a mixed extracting solution B; preparing primary clear paste; perfecting the clear paste; merging the clear paste with essential oil; refrigerating, filtering, bulking and sterilizing, so as to obtain the patulin. The cold medicine is characterized in that the product is an oral solution and is free of a side effect. The citrus and the fructus cnidii are added, so that the taste is better, and the cold medicine does not need to be brewed by water and is more convenient to take. CO2 supercritical extraction is adopted in the preparation process, and the medicinal value loss of the raw materials can be better reduced.
The invention discloses a traditional Chinese medicine compound transdermal gel preparation having the effects of inhibiting inflammation and suppressing pains, and a preparation method thereof. The gel preparation is composed of a traditional Chinese medicine compound composition having the effects of inhibiting inflammation and suppressing pains, a gel matrix and a transdermal absorption penetration enhancer. The medicine composition takes aconite extract and white peony root extract as active ingredients, and has a significant synergic effect in aspects of inhibiting inflammation and suppressing pains. A curative effect is obviously superior to that of aconite total alkaloids or white peony root total glucosides being used individually. The medicine can reach lesions directly by delivering the preparation transdermally. At the same time, security can be further increased. Animal pharmacodynamic tests of the gel preparation show that pharmacological actions for inhibiting inflammation and suppressing pains of the preparation are obvious and definite, thereby providing a pain-relieving compound transdermal preparation which has better clinical curative effect and is more convenient for use.
Global aging is rapidly accelerating, which significantly influences the health systems worldwide. Frailty emerges as the most conspicuous hallmark of aging, imposing novel global health challenges. Characterized by a multifaceted decline across physiological system, frailty diminishes an individual's capacity to maintain equilibrium in the presence of stressors, which leads to adverse outcomes such as falls, delirium, and disability. Several screening tools and interventions have been developed to mitigate the harm caused by frailty to human health, but research on frailty in mainland China commences belatedly with scant studies conducted. Therefore, it is imperative to explore screening methods and treatment modalities tailored to the Chinese context, thereby enhancing the older adults' quality of life and advancing social medicine. This review aims to elucidate the evolution, diagnosis, and management of frailty, alongside the challenges it poses, with the overarching goal of guiding future diagnostic and therapeutic endeavors. Specifically, we summarized the mechanisms of frailty and intervention strategies in elderly people, and meanwhile, we evaluated the advantages and disadvantages of different measurement tools.
Aggregation pathway of amyloid-β (25-35) in water affects the oxidative stress in the brain observed after administration of aggregated peptide in animals in vivo. Our studies on peptide aggregation ex situ prior to injection suggest that from the onset of peptide incubation in aqueous media, all samples exhibit the formation of fibril-like aggregates, characterized by a significant amount of β-sheets. This induces significant oxidative stress in vivo as observed for up to 60 min of peptide aggregation time. As the aggregation advances, the fibril-like aggregates become longer and intertwined, while the amount of β-sheets does not change significantly. An injection of such large, thick, and entangled aggregates in the animal brain results in a drastic increase in oxidative stress. This may be related to the number of activated microglia that initiate a sequence of inflammatory responses in the presence of large, highly interconnected fibrils.
Even though much work has been invested in trying to identify risk factors that can predict which population will suffer from sphincter tears and other pelvic floor trauma, the epidemiology is still poorly understood. Factors that have been implicated to include operative vaginal delivery, birth weight, and primaparity. Up to this point little focus has been placed on antenatal factors that would help predict and prevent sphincter disruptions. At the time of birth the infant's head is the largest part of the body. Thus, head circumference of the infant may be able to predict which subjects is more likely to suffer from sphincter disruption. Thus, this study aims to determine whether or not fetal head circumference measured antenatally is predictive of pelvic floor trauma.
PURPOSE:To improve the permissible amt. of accepting patients by constituting this system in such a manner that confirmation information is outputted of the corresponding okay information exists as a result of retrieval and warning information is outputted as a check result if the okay information does not exist. CONSTITUTION:Prescription information is read into a prescription monitor means 8 from a prescription information storage means 2. The prescription monitor processing of the prescription information is executed by referencing a drug master, compd. master and medical effect master which are respective drug informations of the storage means 3, 4, 5. The okay information corresponding to the kind of the warning is retrieved from the okay information registered in a patient information storage means 6 if the result to be warned is discovered by the above-mentioned processing. Consequently, the confirmation information is outputted as the check result in the case of the presence of the corresponding okay information and the warning information is outputted in the case of the absence of the corresponding okay information respectively to a check list output means 9. As a result, the check result from the prescription monitor means 8 is printed and outputted as the check list of the confirmation information or the check list of the warning information in a check list output means 9.
PURPOSE: A cosmetic composition containing a Betula platyphylla extract having excellent wrinkle-reducing effect and skin and collagenase activity inhibiting effect is provided. The composition has excellent cell regenerating and collagen formation-promoting effect and stability when blended as a cosmetic and thus can be used as a cosmetic effective in decreasing skin wrinkles. CONSTITUTION: The cosmetic composition contains 0.0001 to 5% by weight of an extract of Betula platyphylla var. japonica(Miquel) Hara, based on the total weight of the composition. The Betula platyphylla extract is obtained by soaking 1 to 15 times in a solvent at 4 to 30deg.C for 3 to 20 days or extracting at 50 to 100deg.C for 3 to 24hr. The solvent is selected from water, C1-4 lower alcohol or a mixed solvent thereof and ethylacetate. Before and after the extraction of the Betula platyphylla, a diethylether soluble component is removed from the extract.
Patients were to receive surufatinib plus chemotherapy every 30 days as neoadjuvant treatment. After receiving 2 cycles of treatment, patients will be evaluated for tumor necrosis rate.
This is the comparative group. Participating mothers will receive Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily, starting at gestational weeks 28 and continue until delivery. Patients in group B will have similar follow-up schedules as those in the experimental group. Infants will receive hepatitis B vaccine plus HBIg at birth and additional hepatitis B vaccine at the age of week 4 and week 24.